Product logins

Find logins to all Clarivate products below.


Hypertension | Current Treatment: Physician Insights | US | 2020

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different classes. Nevertheless, despite the numerous treatment options, significant unmet need remains in the treatment of resistant hypertension, which is defined as inadequately controlled BP despite the concurrent use of three or more antihypertensive agents. This report provides cardiologist insight into prescribing patterns for hypertension and especially resistant hypertension.

Questions Answered:

  • What patient shares do angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) garner in the U.S. hypertension market? What are the trends in prescribing for resistant hypertension?
  • How do physicians diagnose resistant hypertension, and how does this diagnosis influence their treatment approach?
  • What factors constrain and what factors drive choice of hypertension treatment?
  • What percentage of hypertensive patients receive monotherapy versus combination therapy?

Product Description:

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

GEOGRAPHY: United States

PRIMARY RESEARCH: Survey of 100 U.S. cardiologists

KEY DRUGS COVERED: ACE inhibitors, ARBs, diuretics, calcium channel blockers, beta blockers, aldosterone antagonists, mineralocorticoid receptor antagonists (MRAs), diuretics, direct renin inhibitors, centrally acting antihypertensives, and alpha blockers.

KEY INSIGHTS PROVIDED: Factors influencing disease management and treatment decisions; drivers of and constraints on treatment selection; physician-reported treatment practices; rationale for changes in treatment approach; physician insight on persistency and compliance; physician-reported recent/anticipated changes in treatment approach.

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Dry Eye – Current Treatment – Current Treatment: Physician Insights – Dry Eye Disease (EU3)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. In Europe, DED has traditionally been managed…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…